Urothelial carcinoma of the urinary bladder is a prime example of the clinical conflict between therapeutic progress and biological resistance. While superficial tumors can often be successfully resected or controlled with intravesical therapies, metastatic or muscle-invasive tumors are often fatal. One of the greatest challenges: cellular resistance to platinum-based chemotherapeutic agents – especially cisplatin, which is still considered the gold standard in systemic therapy.
Autoren
- Tanja Schliebe
Publikation
- Urologie-Special
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Treatment of vitiligo
Focus on patient perspective and disease activity
- Vaccine-preventable respiratory diseases
RSV and pneumococci: recommendations for risk groups
- Circadian rhythm in asthma
Chronotherapy can improve control
- Update on diagnostics, risk stratification and therapy
Acute myeloid leukemia 2025
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Findings from the TRACK-FA study
Neuroimaging biomarkers in Friedreich’s ataxia
- Doing sport without fear or risk
Doing sport without fear or risk
- Chronic inducible urticaria